BR0313234A - Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto - Google Patents

Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto

Info

Publication number
BR0313234A
BR0313234A BR0313234-0A BR0313234A BR0313234A BR 0313234 A BR0313234 A BR 0313234A BR 0313234 A BR0313234 A BR 0313234A BR 0313234 A BR0313234 A BR 0313234A
Authority
BR
Brazil
Prior art keywords
compound
prophylaxis
diseases
preparation
treatment
Prior art date
Application number
BR0313234-0A
Other languages
English (en)
Inventor
Glen Ernst
Eifion Phillips
Richard Schmiesing
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0313234A publication Critical patent/BR0313234A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"COMPOSTO, USO DO MESMO, MéTODO DE TRATAMENTO OU PROFILAXIA DE DOENçAS, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Receptor acetilcolina nicotínico de fórmula (1) na qual D, Ar^ 1^, E e Ar^ 2^ são como definidos no relatório descritivo, enanciómeros, sais farmaceuticamente aceitáveis, métodos de preparação, composições farmacêuticas contendo-os e métodos para uso dos mesmos no tratamento ou na profilaxia de distúrbios psicóticos, distúrbios de enfraquecimento intelectual, mal de Alzheimer, déficit de aprendizado, déficit de cognição, déficit de atenção, perda de memória . Demência de Corpo de Lewy, Distúrbio de Hiperatividade com Déficit de Atenção, ansiedade, esquizofrenia, mania ou depressão maníaca, doença de Parkinson, doença de Huntington, sindrome de Tourette, distúrbios neurodegenerativos nos quais há uma perda de sinapse colinérgica, desorientação temporária, cessação de fumar, dependência de nicotina, dor, colite ulcerativa ou síndrome do intestino irritável.
BR0313234-0A 2002-08-14 2003-08-13 Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto BR0313234A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202430A SE0202430D0 (sv) 2002-08-14 2002-08-14 New Compounds
PCT/SE2003/001277 WO2004016617A1 (en) 2002-08-14 2003-08-13 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists

Publications (1)

Publication Number Publication Date
BR0313234A true BR0313234A (pt) 2005-06-14

Family

ID=20288725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313234-0A BR0313234A (pt) 2002-08-14 2003-08-13 Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto

Country Status (19)

Country Link
US (1) US20050239774A1 (pt)
EP (1) EP1539765B1 (pt)
JP (1) JP2006507241A (pt)
KR (1) KR20060002727A (pt)
CN (1) CN100343256C (pt)
AT (1) ATE417049T1 (pt)
AU (1) AU2003248592B2 (pt)
BR (1) BR0313234A (pt)
CA (1) CA2493920A1 (pt)
DE (1) DE60325234D1 (pt)
ES (1) ES2316848T3 (pt)
HK (1) HK1077571A1 (pt)
IL (1) IL166416A0 (pt)
MX (1) MXPA05001583A (pt)
NO (1) NO20051259L (pt)
NZ (1) NZ537882A (pt)
SE (1) SE0202430D0 (pt)
WO (1) WO2004016617A1 (pt)
ZA (1) ZA200501226B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
KR101129933B1 (ko) 2002-09-25 2012-03-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
WO2004076453A1 (en) * 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives
PL1697378T3 (pl) 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2005061511A1 (en) * 2003-12-22 2005-07-07 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
AU2005210039B2 (en) * 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US20050234095A1 (en) 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
ATE487716T1 (de) 2004-04-22 2010-11-15 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
CA2584836A1 (en) * 2004-10-15 2006-04-20 Neurosearch A/S Novel azabicyclic aryl derivatives and their medical use
CA2591817A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
EP1987032A1 (en) 2006-02-14 2008-11-05 NeuroSearch A/S 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8148365B2 (en) 2006-05-30 2012-04-03 Neurosearch A/S 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20100298306A1 (en) * 2007-10-22 2010-11-25 Memory Pharmaceuticals Corporation (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease
GB0724251D0 (en) 2007-12-12 2008-02-06 Univ Edinburgh Therapeutic compounds and their use
GB0804685D0 (en) * 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
PT2307389E (pt) 2008-06-20 2013-03-28 Astrazeneca Ab Derivados de dibenzotiazepina e sua utilização
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US20120095046A1 (en) 2009-06-15 2012-04-19 The University Of Edinburgh Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders
ES2540547T3 (es) 2009-09-16 2015-07-10 The University Of Edinburgh Compuestos de (4-fenil-piperidin-1-il)-[5-(1H-pirazol-4-il)-tiofen-3-il]-metanona y su uso
MX2012008961A (es) 2010-02-03 2013-04-29 Meh Associates Inc Fluorometanos multiples sustituidos como isosteros selectivos y bioactivos.
WO2011135276A1 (en) 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1
BR112012029237A2 (pt) 2010-05-17 2016-11-29 Envivo Pharmaceuticals Inc forma cristalina de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida monohidratado
JP5996532B2 (ja) * 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
AU2014282977B2 (en) 2013-06-21 2018-06-14 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3281423A (en) * 1964-02-03 1966-10-25 Merck & Co Inc 1, 3-ethanopiperazines and process
US4895943A (en) * 1988-10-25 1990-01-23 Pfizer Inc. Preparation of 1,4-diazabicyclo(3.2.2)nonane
US5679673A (en) * 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
FR2809731B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
FR2809732B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
WO2004076453A1 (en) * 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives
WO2005061511A1 (en) * 2003-12-22 2005-07-07 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
ZA200501226B (en) 2006-07-26
CN100343256C (zh) 2007-10-17
NO20051259L (no) 2005-05-12
WO2004016617A1 (en) 2004-02-26
NZ537882A (en) 2008-02-29
CN1678615A (zh) 2005-10-05
JP2006507241A (ja) 2006-03-02
SE0202430D0 (sv) 2002-08-14
ES2316848T3 (es) 2009-04-16
EP1539765A1 (en) 2005-06-15
HK1077571A1 (en) 2006-02-17
DE60325234D1 (de) 2009-01-22
IL166416A0 (en) 2006-01-15
KR20060002727A (ko) 2006-01-09
US20050239774A1 (en) 2005-10-27
CA2493920A1 (en) 2004-02-26
AU2003248592B2 (en) 2008-04-03
MXPA05001583A (es) 2005-04-25
EP1539765B1 (en) 2008-12-10
ATE417049T1 (de) 2008-12-15
AU2003248592A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
SE9903760D0 (sv) New compounds
BRPI0514032A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
BRPI0514035A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0316375A (pt) Diazinopirimidinas
BRPI0416283A (pt) compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
MXPA04000577A (es) Derivados de dolastatina 10.
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
EE200000472A (et) Kasvajavastased toimeained
PT992509E (pt) Novos derivados macrolidos
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
SE0203300D0 (sv) Novel Compounds
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.